Effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction.
The present study was designed to examine the effects of sodium ozagrel on hemostatic markers and cerebral blood flow in lacunar infarction. Ten cases of lacunar infarction in which sodium ozagrel was given (administered group), 10 cases of lacunar infarction in which sodium ozagrel was not given (nonadministered group), and 10 age-matched controls in which cerebrovascular diseases were absent but risk factors were similar to those of the patients (control group) were studied. Intravenous infusion of 80 mg of sodium ozagrel was done twice a day for 2 weeks. Platelet factor 4, beta-thromboglobulin, and fibrinopeptide A were significantly higher in the administered and nonadministered groups than in the control group at the time of admission. Platelet factor 4, beta-thromboglobulin, fibrinopeptide A, and thromboxane B2 were decreased significantly by the administration of sodium ozagrel. The blood flow in the cerebral cortex was significantly lower in the administered and nonadministered groups than in the control group. The blood flows around the infarcted area, in the cerebral cortex, and in the cerebral white matter were significantly increased by the administration of sodium ozagrel. Sodium ozagrel is considered to decrease platelet aggregation and increase cerebral blood flow by decreasing thromboxane A2, which has a platelet-aggregating and a vasoconstricting action. Sodium ozagrel is considered to be effective in the acute phase of lacunar infarction.
Oishi
M
M
Department of Neurology, Nihon University School of Medicine, Tokyo, Japan.
Mochizuki
Y
Y
Hara
M
M
Yoshihashi
H
H
Takasu
T
T
D000368:Aged; D002544:Cerebral Infarction / Q000097:blood* / Q000188:drug therapy*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005344:Fibrinopeptide A / Q000378:metabolism*; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D018810:Magnetic Resonance Angiography; D008689:Methacrylates / Q000627:therapeutic use*; D008875:Middle Aged; D010978:Platelet Factor 4 / Q000378:metabolism*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D001620:beta-Thromboglobulin / Q000378:metabolism*
D004791:Enzyme Inhibitors; D008689:Methacrylates; D001620:beta-Thromboglobulin; D005344:Fibrinopeptide A; D010978:Platelet Factor 4; D013930:Thromboxane-A Synthase; C034364:ozagrel